On April 27, Novartis announced the results for the first quarter of 2021.
Net sales revenue was US$12.
411 billion (+1%), which was basically the same as last year's first quarter revenue.
Sales in the Chinese market reached 744 million US dollars, an increase of 11%.
Novartis' current business is divided into two main lines: innovative drugs and generic drugs.
In the first quarter, net sales of innovative drugs were US$10.
1 billion (+4%).
The generic drug business was mainly responsible for Sandoz.
Net sales in the quarter were US$2.
3 billion (-9%).
From the perspective of specific products, the rheumatoid immune disease treatment drug Cosentyx (skucilumab) and the new heart failure drug Entresto (sacquatril valsartan) contributed a total of 1.
8 billion US dollars, an increase of 19% year-on-year.
The CAR-T product Kymriah has grown strongly in all regions, reaching US$151 million (+55%).
The product coverage continues to expand and has more than 300 qualified CAR-T treatment centers in 28 countries.
Zolgensma, a gene therapy for spinal muscular atrophy, has benefited from geographical penetration and is currently in an outbreak, with a double-digit growth rate of 88% reaching US$319 million.
In addition, Novartis mentioned in its financial report the PD-1 tislelizumab introduced from BeiGene on January 12.
At this year’s AACR meeting, two key clinical results of tislelizumab were announced.
The median overall survival (mOS) of tislelizumab in the second-line treatment of NSCLC was prolonged by 5.
3 months more than the second-line treatment of the esophagus.
The key study of squamous cell carcinoma also reached its primary endpoint.
Novartis said it will submit a marketing application for these two indications to the FDA before the end of this year.